STOCK TITAN

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Atara Biotherapeutics (Nasdaq: ATRA), a pioneer in T-cell immunotherapy focusing on EBV T-cell platform for cancer and autoimmune disease treatments, has announced its participation in the Stifel 2024 Healthcare Conference. Cokey Nguyen, Ph.D., President and CEO, will engage in a fireside chat on November 18, 2024 at 6:10 a.m. PST / 9:10 a.m. EST.

The presentation will be accessible via live webcast in the Investors and Media section of atarabio.com, with a replay available for 30 days after the event.

Atara Biotherapeutics (Nasdaq: ATRA), un pioniere nell'immunoterapia con cellule T che si concentra sulla piattaforma di cellule T EBV per i trattamenti contro il cancro e le malattie autoimmuni, ha annunciato la sua partecipazione alla Conferenza Sanitaria Stifel 2024. Cokey Nguyen, Ph.D., Presidente e CEO, parteciperà a una conversazione informale il 18 novembre 2024 alle 6:10 a.m. PST / 9:10 a.m. EST.

La presentazione sarà accessibile tramite webcast dal vivo nella sezione Investitori e Media di atarabio.com, con una registrazione disponibile per 30 giorni dopo l'evento.

Atara Biotherapeutics (Nasdaq: ATRA), un pionero en la inmunoterapia con células T centrado en la plataforma de células T EBV para tratamientos de cáncer y enfermedades autoinmunes, ha anunciado su participación en la Conferencia de Salud Stifel 2024. Cokey Nguyen, Ph.D., Presidente y CEO, participará en una charla informal el 18 de noviembre de 2024 a las 6:10 a.m. PST / 9:10 a.m. EST.

La presentación será accesible a través de una transmisión en vivo en la sección de Inversores y Medios de atarabio.com, con una repetición disponible durante 30 días después del evento.

아타라 바이오테라퓨틱스 (Nasdaq: ATRA)는 암 및 자가 면역 질환 치료를 위한 EBV T 세포 플랫폼에 집중하는 T세포 면역 요법의 선두주자로, 스티펠 2024 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 코키 응우옌 박사, 사장 겸 CEO는 2024년 11월 18일 오전 6시 10분 PST / 오전 9시 10분 EST에 대담에 참여할 예정입니다.

프레젠테이션은 atarabio.com의 투자자 및 미디어 섹션에서 생중계로 시청할 수 있으며, 이벤트 후 30일간 다시 볼 수 있는 재생이 제공됩니다.

Atara Biotherapeutics (Nasdaq: ATRA), un pionnier dans l'immunothérapie par cellules T axé sur la plateforme de cellules T EBV pour les traitements du cancer et des maladies auto-immunes, a annoncé sa participation à la Conférence Santé Stifel 2024. Cokey Nguyen, Ph.D., Président et PDG, participera à une discussion informelle le 18 novembre 2024 à 6h10 PST / 9h10 EST.

La présentation sera accessible via un webinaire en direct dans la section Investisseurs et Médias de atarabio.com, avec une rediffusion disponible pendant 30 jours après l'événement.

Atara Biotherapeutics (Nasdaq: ATRA), ein Pionier in der T-Zell-Immuntherapie, der sich auf die EBV-T-Zell-Plattform für Behandlungen von Krebs und Autoimmunerkrankungen konzentriert, hat seine Teilnahme an der Stifel 2024 Healthcare Conference angekündigt. Cokey Nguyen, Ph.D., Präsident und CEO, wird am 18. November 2024 um 6:10 Uhr PST / 9:10 Uhr EST an einem Gespräch teilnehmen.

Die Präsentation wird über einen Livestream im Bereich Investoren und Medien auf atarabio.com verfügbar sein, mit einer Wiederholung, die 30 Tage nach der Veranstaltung zur Verfügung steht.

Positive
  • None.
Negative
  • None.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 6:10 a.m. PST / 9:10 a.m. EST.

A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.

Investor and Media Relations:

Jason Awe, Ph.D.

Head of Corporate Communications & Investor Relations

(805) 217-2287

jawe@atarabio.com

Source: Atara Biotherapeutics, Inc.

FAQ

When is Atara Biotherapeutics (ATRA) presenting at the Stifel 2024 Healthcare Conference?

Atara Biotherapeutics will present at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 6:10 a.m. PST / 9:10 a.m. EST.

How can I watch Atara Biotherapeutics' (ATRA) presentation at the Stifel 2024 Healthcare Conference?

The presentation can be viewed via live webcast in the Investors and Media section of atarabio.com, with a replay available for 30 days following the live presentation.

What type of therapies does Atara Biotherapeutics (ATRA) develop?

Atara Biotherapeutics develops T-cell immunotherapy treatments using their allogeneic Epstein-Barr virus (EBV) T-cell platform for patients with cancer and autoimmune diseases.

Atara Biotherapeutics, Inc

NASDAQ:ATRA

ATRA Rankings

ATRA Latest News

ATRA Stock Data

60.31M
4.46M
22.15%
50.83%
11.21%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS